BioCentury | Apr 19, 2019
Company News

FDA approves Ibrance for men with breast cancer

...treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in men in combination with an aromatase...
BioCentury | Feb 1, 2019
Company News

Pfizer launches China's first pay-for-performance model for cancer

...metastasis within the first 126 days of starting treatment with Ibrance in combination with an aromatase...
...and CDK6, gained Chinese approval in August to treat breast cancer in combination with an aromatase...
BioCentury | Jan 25, 2019
Company News

Pfizer launches China's first pay-for-performance model for cancer

...metastasis within the first 126 days of starting treatment with Ibrance in combination with an aromatase...
...and CDK6, gained Chinese approval in August to treat breast cancer in combination with an aromatase...
BioCentury | Jan 4, 2019
Company News

Xynomic returns to Boehringer for second cancer candidate

...Phase I trials for solid tumors as a single agent and in combination with an aromatase...
BioCentury | Nov 2, 2018
Clinical News

Syndax's entinostat misses PFS endpoint in Phase III for breast cancer

...patients with hormone receptor-positive, HER2-negative breast cancer whose disease progressed following treatment with a non-steroidal aromatase...
BioCentury | Oct 26, 2018
Clinical News

Syndax slides on entinostat PFS miss in breast cancer

...patients with hormone receptor-positive, HER2-negative breast cancer whose disease progressed following treatment with a non-steroidal aromatase...
BioCentury | Oct 26, 2018
Company News

NICE recommends against abemaciclib for untreated breast cancer

...the use of Verzenio abemaciclib from Eli Lilly and Co. (NYSE:LLY) in combination with an aromatase...
...of Verzenio in to treat advanced hormone-receptor positive, HER2-negative breast cancer in combination with an aromatase...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Stepping Through

...ribociclib from Novartis AG. It had been approved as first-line therapy in combination with an aromatase...
BioCentury | Aug 31, 2018
Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

...receptor-positive, HER2-negative men and postmenopausal women with or without the PI3KCA mutation who progressed following aromatase...
...advanced or metastatic estrogen receptor-positive, HER2-negative, PI3KCA-mutant breast cancer who relapsed after treatment with an aromatase...
BioCentury | Aug 23, 2018
Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

...receptor-positive, HER2-negative men and postmenopausal women with or without the PI3KCA mutation who progressed following aromatase...
...advanced or metastatic estrogen receptor-positive, HER2-negative, PI3KCA-mutant breast cancer who relapsed after treatment with an aromatase...
Items per page:
1 - 10 of 260